C4 Therapeutics expands discovery platform to accelerate development of molecular glue degraders

C4 Therapeutics expands discovery platform to accelerate development of molecular glue degraders
C4 expands discovery platform

C4 Therapeutics has expanded its discovery platform to help identify novel molecular glue degraders. The company is using its DNA-encoded library (DEL) to create an efficient hit-finding engine for the rapid development of targeted protein degraders.

The move aims to advance C4 Therapeutics' capabilities in drug discovery and enhance the speed at which new degraders are identified and developed.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.